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Abstract 
Localized, non-indolent prostate cancer (PCa) is characterized by large-scale genomic 
rearrangements, aneuploidy, chromothripsis, and other forms of chromosomal instability (CIN), 
yet how this occurs remains unclear.  A well-established mechanism of CIN is the 
overproduction of centrosomes, which promotes tumorigenesis in various mouse models.  
Therefore, we developed a single-cell assay for quantifying centrosomes in human prostate 
tissue. Surprisingly, centrosome loss - which has not been described in human cancer - was 
associated with PCa progression.  By chemically or genetically inducing centrosome loss in non-
tumorigenic prostate epithelial cells, mitotic errors ensued, producing aneuploid and 
multinucleated cells. Strikingly, transient or chronic centrosome loss transformed prostate 
epithelial cells which produced highly proliferative and poorly differentiated malignant tumors in 
mice.  Our findings suggest that centrosome loss could create a cellular crisis with oncogenic 
potential in prostate epithelial cells.  
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Introduction 
Tumorigenic driver mutations, common in other cancers, have not been detected in primary 
prostate tumors [1-3].  Indeed, localized PCa contains an overall low burden of single nucleotide 
variants (SNVs), while metastatic PCa has multiple specific recurrently altered genes and 
pathways [3-7]. Instead, primary PCa displays nuclei with defects in size and DNA content, and 
enriched with large-scale genomic rearrangements, copy number variations (CNV), changes in 
DNA methylation patterns, chromothripsis, gene fusions and other forms of genomic instability 
[8-10].  By analyzing the clonal status of genomic lesions within prostate tumors, a model has 
been proposed whereby oncogenic genomic alterations occur in a few successive bursts [1]. 
Mutations accumulate slowly at first, and a subset of driver mutations occurs late in PCa 
development [1, 11].  Thus, oncogenic events for localized PCa might include an unidentified 
mechanism, independent of specific driver mutations, to generate an early genomic crisis.   
A genomic crisis could arise due to a change to centrosome numbers.  Centrosomes are 
the major microtubule-organizing center in cells, giving rise to a variety of protein machines, 
including mitotic spindles [12].  At the centrosome core lies a centriole pair that serve as the 
duplicating elements of the organelle and recruit an organized shell of pericentriolar material 
possessing microtubule-nucleating activity [13, 14].  Cells exert tight control over centrosome 
copy number because centrosome overduplication (known as ‘amplification’) or centrosome loss 
produce cellular dysfunction and disease [15, 16].  
Centrosome amplification is recognized as a general feature of tumors, seen in several 
solid tumors and blood cancers, and correlates with advanced tumor grade, recurrence, and poor 
survival [17].  Excess centrosomes lead to assembly of transient multipolar spindles with 
incorrect chromosome attachments [18, 19].  Consequently, anaphase lagging chromatids are 
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produced, forming micronuclei susceptible to chromothripsis [20].  Induction of centrosome 
amplification in mice promotes tissue hyperplasia, and formation of solid tumors with focal CNV 
and whole chromosome aneuploidy [21-24].   
In the opposite condition, vertebrate cells lacking centrosomes use an acentrosomal 
microtubule assembly pathway [25], and their proliferation is dependent on p53 status [26-28].  
Acentrosomal spindles cause prolonged mitosis as well as mitotic errors including anaphase 
lagging chromatids, micronuclei, aneuploidy, and polyploidy [27-30].  Although centrosome 
amplification and loss have remarkably similar effects in promoting CIN, centrosome loss has 
not been reported in cancer. 
Here, we show that human prostate tumors display significant centrosome loss.  Moreover, 
centrosome loss in non-tumorigenic prostate epithelial cells results in genomic alterations and 
malignant mouse xenograft tumors.  Our results suggest that centrosome loss is a cellular crisis 
in prostate cancer, potentially explaining the presence of large-scale genomic defects without 
specific recurrent mutations.   
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Results 
Localized prostate tumors display significant centrosome loss with increasing grade 
Localized prostate cancer was analyzed for centrosome detection and quantitation using an in 
situ immunofluorescence microscopy assay developed by us [35].  Since a pair of centrioles form 
the centrosome core, antibodies were used against centriole protein CEP135 and the PCM 
protein γ-Tubulin; co-localization of CEP135 and γ-Tubulin foci confirmed our ability to detect 
bona fide centrosomes (Fig. S1).  E-Cadherin staining demarcated epithelial cell borders.  
Localized PCa shows elevated E-cadherin expression and, although no significant differences in 
E-Cadherin expression associate with higher Gleason scores [36], we used α6 integrin as an 
additional membrane marker.   
Tissues were imaged in multiple z-sections, and although centrosomes are small, our 
approach reliably identified cell boundaries and maximized our ability to image entire cell 
volumes, allowing us to measure centrosomes within individual cells. Normal human prostate 
glands possess basal and luminal cell layers (Fig. 1a). CEP135 localizes to the proximal end of 
each centriole within the pair and, as expected, appeared as two distinct spots in the majority of 
basal and luminal cells (Fig. 1a, f).  Each cell contained two CEP135 foci that could be 
positioned in different z-section planes or within the same focal section (Fig. 1a).  
Approximately 20% of cells in normal prostate glands contained no centrosomes (Fig. 1f), likely 
due to the known loss of cell content during tissue sectioning.  Surprisingly, Gleason grade 3 
PCa exhibited a significant increase in cells lacking centrosomes compared to cells of normal tissue.  The proportion of cells devoid of centrosomes increased significantly with each increase 
of tumor grade: 52% for Gleason grade 4 and 73% for Gleason grade 5.  This pattern held true 
when centrosome numbers are counted using CEP135 or γ-Tubulin foci (Fig. 1b, c, and f).  
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Importantly, centrosomes were readily observed in surrounding normal stromal cells, 
distinguished as cells lacking E-Cadherin and serving as an internal control (Fig. 1c, yellow 
arrowheads). Detection of centrosomes in stromal cells demonstrated that our assay can identify 
centrosomes in cells with small volumes within the same section. 
As a further validation for our assay, we quantified centrosomes in triple-negative breast 
cancer (TNBC), which is known to display centrosome amplification [37]. Compared to normal 
mammary glands, we confirmed that TNBC contains a significantly higher fraction of cells with 
>2 CEP135 foci (24%) (Fig. 1d-f). Since TNBCs contain low levels of differentiation markers 
and lack basal-apical polarity [38], our assay is effective regardless of cell polarity or 
differentiation status. Thus, unlike most epithelial cancers described to date, centrosomes are lost 
in localized PCa and in prostate tumors with higher Gleason scores.  
 
PCa cell lines show both centrosome amplification and loss 
We next compared centrosome numbers in primary and immortalized non-tumorigenic prostate 
epithelial cells as well as metastatic and neuroendocrine PCa-derived cell lines. Cells were 
immunostained for CEP135 and CENT3 (an additional centriole marker) or γ-Tubulin, and the 
numbers of foci per cell were measured. Most prostate epithelial cells (80%), including PEC 
(primary) as well as PrEC, iPEC37, and RWPE1 (immortalized), contained a normal centrosome 
count (two CEP135 foci per cell) while few displayed centrosome loss (zero CEP135 foci per 
cell) or amplification (>2 CEP135 foci per cell) (Fig. 2a-d, j). However, metastasis-derived PCa 
cell lines displayed either centrosome loss or amplification and could be sub-classified by their 
androgen receptor expression status.  Androgen-responsive cell lines, LNCaP and VCaP, showed 
significant centrosome loss compared to RWPE1 cells (Fig. 2e, f, j).  Similar loss of centrosomes 
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in LNCaP cells was previously reported [39].  In contrast, castration-resistant DU145 and PC3 
cells, and neuroendocrine H660 cells, displayed centrosome amplification (Fig. 2g-j), as 
previously described [39, 40].  Thus, centrosome numbers during tumor progression may be 
dynamic.  While a majority of primary prostate PCa in situ show centrosome loss, centrosome 
amplification appears in more clinically-aggressive variants of hormone-resistant metastatic 
cancer.   
 
Centrosome loss in prostate epithelial cells results in mitotic errors, chromosome 
fragmentation, and micronuclei   
We next sought to determine whether the centrosome loss in localized PCa could account for the 
abundant genomic alterations reported [5]. To test this, we used two immortalized prostate 
epithelial cell lines, RWPE1 and PrEC; both have been used as stable, benign in vitro models 
[33, 41-44] and contain normal centrosome numbers (Fig. 2j). We first induced centrosome loss 
chemically by treating cells with centrinone, a Polo-like kinase 4 (Plk4) inhibitor [28].  Plk4 is 
the master-regulator of centriole duplication [45, 46], and its inhibition causes progressive 
centrosome depletion in proliferating cell cultures [28]. Over 90% of cells contained either one 
or zero centrosomes after a 10-day treatment but reassembled centrosomes within two days after 
centrinone removal (Fig. 3a).  As a control for off-targeting effects, we generated a centrinone-
resistant RWPE1 line, designated RWPE1-Plk4 (G95L), by substituting Leu for Gly95 (G95L) 
within the endogenous Plk4 gene using CRISPR/Cas9 [28].  Centrinone had no effect on 
centrosome number in RWPE1-Plk4 (G95L) cells after 10 days of drug treatment (Fig. 3b). 
We next determined how centrosome loss affected mitosis in prostate epithelial cells 
using cells stably expressing histone H2B–GFP and centriole marker CETN1-tdTomato. After a 
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10-day mock or centrinone treatment, we identified live cells with and without centrosomes 
(based on the CETN1 signal) and imaged chromosomes as cells progressed through mitosis by 
time-lapse microscopy (Fig. 3c and Supplementary Videos 1, 2).  Whereas mock and DMSO-
treated cells spent ~102 minutes in mitosis (defined here as nuclear envelope breakdown to 
telophase) (Fig. 3d, Supplementary Videos 3, 4), centrinone-treated cells lacking centrosomes 
spent 3-4 times longer in mitosis (Fig. 3d, Fig. S2a, Supplementary Videos 5, 6).  Consequently, 
the mitotic index of centrosome-less cells increased 5-fold but remained similar to control 
frequencies when centrinone was applied to RWPE1-Plk4 (G95L) cells (Fig. S2b), 
demonstrating that the rise in mitotic index was due to Plk4 inactivation.  
In centrinone-treated RWPE1 and PrEC cells, chromosomes clustered on disorganized 
spindles during a prolonged prometaphase (Fig. 3e, f, Supplementary Video 7), but eventually 
separated into two chromosome masses (Fig. 3c, Supplementary Videos 5-8).  Lagging 
chromatids were present during anaphase (Fig. 3c, red arrowheads, Supplementary Videos 5, 6), 
which have been shown to form from abnormal merotelic kinetochore attachments in 
acentrosomal vertebrate spindles [30, 47]. Strikingly, we detected several small chromosomes 
surrounding the central chromosome mass(es) (Fig. 3c, e) and that were inefficiently captured by 
spindles (Fig. 3f, yellow arrowheads).  Immunostaining for the centromere protein CENP-C 
revealed these errant chromosomes lacked centromeres and, thus, are chromosome fragments 
(Fig. 3f, Supplementary Video 7).  Mis-segregated chromosome fragments were enveloped into 
micronuclei during mitotic exit, causing an increase of micronuclei frequency that was not seen 
in RWPE1-Plk4 (G95L) cells (Fig. 3g and Fig. S2c).  Cytokinesis failure was also frequent 
(30%; 20 of 66 cells) in centrinone-treated cells (Fig. 3c, RWPE1), and continuous imaging 
revealed that 80% of these cells died soon after entering G1-phase. As an alternative to 
 9 
centrinone, we generated two Plk4- null clonal lines using CRISPR (Plk4KO-1 and Plk4KO-2) 
(Fig. S2d, e); immunostaining for CEP135 and γ-Tubulin confirmed that both clones lacked 
centrosomes. Both Plk4KO-1 and KO-2 clones showed a significant increase in the frequency of 
micronuclei (Fig. 3g).  Notably, 61% of micronuclei in centrinone-treated RWPE1 cells lacked 
CENP-C (Fig. 3h), suggesting that most micronuclei formed from chromosome fragments.  
Lastly, we examined whether centrosome loss also generates micronuclei in 3-
dimensional (3D) cultured spheroids that approximate normal prostate glands [48].  Similar to 
2D cultures, centrinone-treatment produced spheroids with numerous micronuclei (Fig. 3i, 
arrowheads).  Taken together, our findings suggest that centrosome loss in cultured prostate 
epithelial cells induces phenotypes known to promote CIN. 
 
Centrosome loss produces abnormal nuclear envelopes and increased multinucleate cells in 
PCa tissue   
We next imaged chromosomes of cultured cells exiting mitosis by time-lapse microscopy. 
Interestingly, we observed mitotic cells that formed multi-nucleated daughter cells as well as 
abnormally-shaped, multi-lobed nuclei in spite of having no apparent defects in anaphase 
chromosome segregation or cytokinesis (Fig. 4a, Supplementary Videos 9, 10).   
Since cells of early PCa contain nuclei with morphological defects [9], we analyzed 
whether centrosome loss results in defects in nuclear morphology by immunostaining cells for 
nuclear lamina proteins, Lamin A/C or Emerin.  Plk4KO PrEC cells or centrinone-treated wild-
type PrEC (or RWPE1) cells displayed a significant 3-9 fold increase in multinucleation 
frequency compared to control cells (Fig. 4b-d).  Nuclear envelopes in acentrosomal cells 
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frequently displayed invaginations (Fig. 4b, arrowheads), irregularities commonly seen in cancer 
cells [49].   
Next, we examined whether similar nuclear defects were present in localized human PCa 
tissue by immunostaining for Lamin A/C or Emerin (Fig. 4e). Compared to cells from normal 
prostate glands, Gleason grade 3 PCa showed a higher average frequency of multinucleated cells 
but this was not significantly different (Fig. 4f). Gleason grade 4 PCa had an almost 4-fold 
increase of multinucleated cells (Fig. 4e, 1 and 2, and f) and micronuclei were detected (Fig. 4e, 
2’ arrowhead). Co-staining for CEP135 and DNA revealed that approximately 70% of 
multinucleated cells displayed complete centrosome loss (Fig. 4g, h).  Taken together, our 
findings suggest that centrosome loss promotes multinucleation and defects in nuclear envelope 
morphology in cultured cells, and these defects are also present in higher grade PCa.  Although it 
is unclear how these defects arose, it is noteworthy that normal nuclear envelope shape and the 
efficiency of nuclear reformation rely on the suppression of microtubule growth near chromatin, 
which happens to be the primary site of microtubule assembly in mitotic cells lacking 
centrosomes [25, 50].  
 
Centrosome loss results in aneuploidy and chromosomal rearrangements   
Localized PCa displays numerical and structural CIN [51].  Since centrosome loss in dividing 
prostate epithelial cells promotes mitotic errors, we evaluated if centrosome loss could induce 
aneuploidy by measuringchromosome numbers from chromosome spreads of mitotic RWPE1 
cells (Fig. 5a, b).  Whereas mock and DMSO-treated cells had a near diploid average 
chromosome number (mock cells: average = 50; DMSO cells: 48) as previously reported [41], 
centrinone treatment induced aneuploidy, significantly increasing the average chromosome 
 11 
number to 69 (Fig. 5b).  Chromosome fragments were also detected (Fig. 5a, arrowheads), 
consistent with our live-cell imaging data and the chromosome fragmentation reported in cells 
with micronuclei [20]. Flow cytometry confirmed that centrinone induced aneuploidy, displaying 
a 6-fold increase in the >4N population (Fig. 5c). DNA profiles of RWPE1-Plk4 (G95L) cells 
(with or without centrinone) remained similar to DMSO-control cells (Fig. 5c), suggesting that 
changes in chromosome number were due to centrosome loss.   
Using spectral karyotyping (SKY), we next examined which specific chromosome 
exceeded diploidy in aneuploid, acentrosomal RWPE1 cells. Cells without centrosomes have 
altered chromosome copy numbers (gains and losses) compared to control cells, but primarily 
showed gains not specific to any particular chromosome (Fig. 5d-g). Cells that were stimulated 
to grow (with FBS) and centrinone-treated to deplete their centrosomes had a sharply increased 
chromosome number compared to FBS-mock treated cells whose karyotype was consistent with 
a previous report (Fig. e) [41]. The frequency of near tetraploid karyotypes (>80 chromosomes) 
also increased by 30% after centrinone treatment, suggesting that cytokinesis failure likely 
contributed to some karyotypes. Furthermore, both RWPE1 cells and PrEC cells showed 
chromosomal structural rearrangements after centrinone treatment (Fig. S3a, b). Thus, instead of 
specific mutations, centrosome loss appears to generate gross genomic abnormalities.  
 
Centrosome loss can stimulate malignant xenograft tumor formation  
Our findings suggest that centrosome loss is a relatively early occurrence in localized PCa, 
producing CIN.  We next determined if centrosome depleted non-tumorigenic prostate cells 
could generate xenograft tumors.   PrEC-Plk4KO clones (clones which proliferate while 
chronically acentrosomal) were injected subcutaneously into male immunodeficient NSG mice 
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and examined for tumor formation weekly for approximately 16 weeks. Parental PrEC cells did 
not form tumors (Fig. 6a), consistent with a previous study [33]. Tumors were not detected by 
palpation of live mice injected with the PrEC-Plk4KO-1 or 2 cell lines.  However, after these 
mice were sacrificed on day 112, tumors were found at 25% of the Plk4KO injection sites (Fig. 
6a).  The tumors were poorly differentiated and malignant as determined by histological 
examination.  Indeed, tumors from both clones invaded into the surrounding adipose and muscle 
tissue (Fig. 6b). Notably, these tumors contained mitotic figures (Fig. 6c, red arrowhead), 
enlarged nuclei (green arrowhead), and multinucleated cells (yellow arrowheads), suggesting that 
tumor cells experience CIN and had histological characteristics of aggressive cancer.  
Although centrosome depletion was sufficient to generate tumors, Plk4KO cells likely 
experience a continuous, high rate of CIN due to their acentrosomal state, which may explain the 
slow growth and hence small size of these tumors. To test this, we used an alternative to chronic 
centrosome absence by transiently depleting centrosomes with centrinone for several days, 
thereby potentially inducing a burst of CIN in the parental PrEC line.  After removal of the drug, 
centrosomes reappeared within the cell population, with the expectation that the potentially 
altered genomes would then be relatively stably-maintained and passed to progeny cells (outlined 
in Fig. 6d).. Accordingly, PrEC cells were treated with centrinone for 15 days (>90% of cells 
contained one or zero centrioles by day 10; Fig. 3a), followed by monoclonal expansion in 
normal culture media without centrinone. Using this approach, three of the ten generated clones 
(CTN-1, 6, and 9) displayed elevated MYC and ERG levels compared to the original PrEC cells 
(Fig. S4a, b). We selected these three lines for xenograft testing because elevated levels of MYC 
and ERG correlate with PCa progression [52, 53]. CTN clones were genomically verified to be 
derived from PrEC using a STR profile.  All CTN clones reestablished normal centrosome 
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numbers after removal of the drug, similar to parental PrEC cells (Fig. S4c). Importantly, 
although the three CTN clones had normal centrosome numbers, they continued to display 
hallmarks of CIN and showed a significant, elevated frequency of micronuclei (Fig. S4d).  All 
three strains inherited CIN from centrinone treatment, displaying dramatic deviations in 
chromosome number compared to the parental line; CTN-1 and CTN-6 showed chromosome 
loss, while CTN-9 had chromosome gain (Fig. S4e). Chromosomal rearrangements were also 
observed in CTN-9 by SKY analysis (Fig. S3b and S5a, b).  
Next, the CTN clones were subcutaneously injected into male immunodeficient NSG 
mice to evaluate their tumorigenicity. As observed with the parental line, mice injected with 
CTN-1 did not form tumors (0 of 12) (Figs. 6e, f). Strikingly however, two CTN clones (CTN-6, 
3 of 12; CTN-9, 9 of 12) formed large, visible tumors at the injection sites; the CTN-9 tumors 
developed much sooner than CTN-6 (80 days versus ~100 days, respectively) (Fig. 6e, f). 
Histological examination of all tumors revealed that they were similar regardless of the specific 
injected clone, forming highly proliferative malignant tumors with poorly differentiated 
epithelial glands (Fig. 6g). Similar to PrEC-Plk4KO clones, both CTN clones formed tumors that 
invaded the surrounding smooth muscle and adipose tissue (Fig. 6h, arrowheads). Thus, transient 
centrosome elimination can transform cells, enabling them to form malignant tumors. 
We further characterized the CTN tumors by immunostaining tissue sections with a panel 
of epithelial, mesenchymal, and secretory markers (Fig. S5c, d). CTN tumors maintained 
epithelial proteins including CD49f and CD44 but were negative for E-cadherin, CK5/14, 
CK8/18, CK14-16, 19, as well as luminal (FOXA1), neuroendocrine (synaptophysin), and 
mesenchymal (vimentin, desmin) markers (Fig. S5c, d). Tumors were highly secretory and 
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stained positive for mucin and hyaluronic acid (HA) (Fig. S5c, d), a feature of poorly 
differentiated malignant PCa [54].  
Lastly, we measured centrosome numbers within all 12 tumors using our in situ 
centrosome-counting assay.  As in PCa tissue, we identified individual cells that clearly 
contained CEP135-labeled centrosomes (Fig. 6i). Dividing cells were also observed and formed 
mitotic spindles regardless of their centrosome status (Fig. 6j). Surprisingly, many tumor cells 
displayed centrosome loss, in some CTN-9 tumors, the percentage of cells with zero centrosomes 
exceeded 70% (Fig. 6k).  Thus, transient removal of centrosomes was sufficient to induce tumor 
formation in a subset of immortalized prostate epithelial PrEC cells.  During tumorigenesis, 
centrosomes were lost in a large population of cells resident at the initial injection site, 
resembling the phenomenon we observed in primary prostate carcinoma. 
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DISCUSSION 
In lieu of signature driver mutations that distinguish many cancers, genomic instability itself may 
provide the primary oncogenic force behind prostate tumorigenesis.  Localized PCa show 
widespread genomic rearrangements, including chromothripsis (20% of tumors) [5].  Moreover, 
genomic alterations occur in a few successive bursts, likely initiated by a genomic crisis, leading 
to a proposed punctuated-progression model of prostate tumor evolution [1, 11].  Extensive 
studies have been performed to understand the complexity of genomic instability in prostate 
tumors and our findings point to centrosome loss as a potential origin of genomic crisis. 
Centrosome loss is prevalent in localized primary prostate carcinoma, becoming more 
pronounced in higher Gleason grade tumors.  Centrosome loss also promotes aneuploidy, 
chromosome fragmentation, micronuclei, and other forms of CIN.  Thus, centrosome loss, in 
principle, may account for the wide range of genomic hallmarks assigned to localized PCa.  
Transient centrosome loss produced much larger solid tumors, suggesting that bursts of genomic 
crisis may be more suitable for sustained proliferation.  Centrosome amplification has been 
recognized by many as a cancer hallmark with the capacity to promote oncogenesis [15].  It is 
surprising that the opposite situation, the absence of centrosomes in proliferating tumor cells, has 
not been described before in human cancer. Similar to multi-centrosomal/multipolar spindles, 
acentrosomal spindles display errors in positioning chromosomes and high rates of CIN [30]. We 
observed that centrosome depletion in human epithelial prostate cells is transformative, enabling 
the previously non-tumorigenic cells to form malignant tumors in mice. Future studies should 
determine whether centrosome loss is a phenomenon restricted to PCa. 
If centrosome loss is a driver of genomic instability in early prostate tumors, what then 
causes this organelle to disappear?  In general, little is known about the mechanisms of 
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centrosome elimination. However, centrosomes are normally inactivated or lost during specific 
developmental stages in different animals [55]. For example, in the Drosophila female germline, 
centrioles disassemble when PCM is down-regulated; this mechanism contributes to centriole 
elimination in the oocyte [56].  In contrast, pericentrin, a PCM component, accumulates in 
prostate carcinoma [57], suggesting that changes in PCM levels may not be a mechanism 
underlying centrosome disappearance in primary prostate tumors. Centrosome loss may be due 
to other factors such as age, inflammation, hypoxia, other environmental influences, or a 
combination of events. Determining the root cause of centrosome disappearance will be an 
important line of investigation. Indeed, an unidentified environmental factor(s) might be 
responsible for the loss of centrosomes from the xenograft tumors that arose from injections of 
cells that had been transiently centrosome-depleted but contained a normal centrosome number 
at the time of injection. 
Although centrosome loss occurs in primary prostate tumors, TNBC displays centrosome 
amplification [38], as do metastatic-derived androgen unresponsive PCa cell lines and 
neuroendocrine H660 PCa cells.  Possibly, centrosome numbers fluctuate during prostate tumor 
evolution.  Indeed, centrosome loss may be an early ‘driver’ event and, through further genomic 
instability, gives rise to cells with genotypes that trigger centrosome amplification, paving the 
way to malignancy.  Notably, centrosome amplification promotes an invasive cellular behavior 
[58, 59].  Additional studies will be needed to determine when centrosome loss occurs in PCa.  
Moreover, we found a possible relationship between centrosome duplication and hormone 
receptor status.  Specifically, clinically-aggressive variants of hormone-resistant metastatic 
cancer show centrosome amplification, raising the possibility that androgen receptor signaling 
might regulate centrosome duplication, which should be explored.  For PCa, this is significant 
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because loss of androgen signaling and gain of neuorendrocine features are indicative of 
increased lethality.  In addition, changes in centrosome number could be used as a predictive 
biomarker for aggressive (high risk) disease and patient survival if it were established that 
centrosome numbers vary in tumors of different malignancies, particular those that are metastatic 
and recurrent. 
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Materials and Methods 
Cell culture   
RWPE1 (ATCC #CRL- 11609TM), PEC, and iPEC37 (C. Miranti, University of Arizona) cells 
were grown in Keratinocyte Serum Free Medium (K-SFM; ThermoFisher) with 0.05 mg/ml 
BPE, 5 ng/ml EGF and penicillin/streptomycin/amphotericin (5% CO2 at 37oC). PEC was 
derived from prostatectomy specimens and verified to be free of stromal contamination [31, 32]. 
Immortalized human PrEC cells (W. Hahn, MIT) [33] were cultured in Iscove’s Modified 
Dulbecco’s Medium (IMDM; ThermoFisher) with 10% FBS. iPEC37 are PEC cells 
immortalized with HPV E6/E7 and hTERT [33]. LNCaP (ATCC C#RL-1740), VCaP (ATCC 
#CRL-2876), and PC3 (ATCC #CRL-1435) were cultured in RPMI 1640 (ThermoFisher) with 
10% FBS, DU145 (ATCC #HTB-81) in IMDM, and NCI-H660 (ATCC #CRL-5813) in RPMI-
1640 media (supplemented with 0.005 mg/ml insulin, 0.01 mg/ml transferrin, 30 nM sodium 
selenite, 10 nM hydrocortisone, 10 nM beta-estradiol, 2 mM L-glutamine, and 5% FBS. Cell 
identities were verified using genomic probes [34].  For RWPE1 cultured in KSFM, centrinone 
was used at 100 nM, but 300 nM for all cells cultured in FBS. Cells were serum starved for 48 
hrs before addition of 100 nM DHT.  
 
Stable lines and CRISPR/Cas9  
Lentiviral plasmid (pLenti6) and packaging vectors (pMD2.G/psPAX2; Addgene #12259 and 
12260) were used to generate H2B-GFP stable expressing cells.  Virus was harvested from HEK-
293 cells at 24-48 hrs post-transfection, filtered, and added to media with 8 μg/ml polybrene. 
Stable lines were selected with 500 ng/ml puromycin after 2 weeks.  RWPE1 lines were then 
transduced with centrin1/CETN1)-tdTomato lentivirus (pLentiLox CMV; V. Bautch, University 
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of North Carolina).  The Alt-R CRISPR/Cas9 system (IDT) with Plk4 gRNA 
(GGAAGCTGAGTGTTAAGTTC) was used to generate Plk4(G95L) [31]. The RNP complex of 
Plk4-crRNA, CRISPR-Cas9 tracrRNA (IDT #1072532), and Cas9 were transfected into cells 
using a Nucleofector 2b (Amaxa).  Repair template plasmid (pY181) (K. Oegema, University of 
California San Diego) and packaging plasmids (pHelper/pAAV-RC) were transfected into 
HEK293T cells using Lipofectamine300.  Virus was harvested 48 hrs post-transfection, filtered, 
and added to media for 16 hrs.  Cells were selected in 96-well plates for two weeks in 0.5 mg/ml 
G418, and homozygous G95L knock-in clones were identified by PCR and sequencing of 
genomic DNA. UACC Genome Editing Facility generated Plk4 homozygous knock-out PrEC 
cells.  Double-strand break sites flanking the Plk4 transcriptional unit (4:127,879,990 and 
4:127,909,266) were targeted with guide sequences 5-AACTACGGAATAAGCGGTAG-3 and 
3-TCTCGCCAACTTAATTAAGG-5. Cells were transfected with Cas9, crRNAs, and tracrRNA 
using Lipofectamine. Two days post-transfection, cutting efficiency was estimated using a T7 
endonuclease assay employing PCR primers flanking the predicted ligation-junction product. 
Single cells were deposited in 96-well plates using the UACC Flow Cytometry Shared Resource 
and colonies were screened by PCR. Clones that were negative for two fragments internal to the 
targeted deletion but positive for ligation-junction fragment were potentially homozygous for the 
deletion. Absence of Plk4 RNA was confirmed by rt-PCR.  
  
Microscopy   
For IF, cells were cultured on coverslips, washed in PBS, and fixed in ice-cold methanol for 10 
mins.  After a 5 min rehydration in PBS, cells were washed in Buffer-A (PBS, 0.5% Triton X-
100) for 5 min, blocking Buffer-B (PBS, 5% NGS, 0.1% Triton X-100) for 30 min, and 
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incubated with primary antibodies in Buffer-B for 1 hr at room temperature.  Next, cells were 
washed 3 times in Buffer-A, incubated with secondary antibodies and Hoechst33342 for 1 hr at 
room temperature, washed 3 times in Buffer-A (5 min), and mounted in 0.1M n-propyl gallate, 
PBS, 90% (by volume) glycerol.  For centromere immunostaining, cells were rinsed in PHEM 
(60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 4 mM MgSO4·7H20), permeabilized with 0.5% 
Triton X-100 in PHEM for 4 min, and fixed with 4% paraformaldehyde in PHEM for 20 min at 
room temperature.   
For metaphase spreads, cells were treated with 0.06 µg/ml colcemid overnight, 
trypsinized, resuspended in Buffer-M (40 mM KCl, 20 mM HEPES, 0.5 mM EGTA, and 9 mM 
NaOH), and incubated for 50 min at 37oC.  Next, cells were fixed in methanol:acetic acid (3:1), 
pelleted, and washed in fixative before dropped onto a pre-cleaned coverglass.  Cells were dried 
on slides for 3 days and stained with Hoechst33342. Spectral karyotyping analysis was 
performed by the Roswell Park Cancer Institute Cytogenetics SKY Core Laboratory. Formalin-
fixed de-identified human cancer tissues were processed for detection of centrosomes using our 
published procedure [35]. Specimens were imaged using a DeltaVision Core equipped with an 
Olympus IX71 microscope, 60X objective (1.42NA), and a cooled charge-coupled CoolSNAP-
HQ2 camera.  For time-lapse microscopy, cells were grown in 8-well Lab-Tek chambered 
coverglass coated with anti-β1 integrin/AIIB2 antibody to inhibit cell migration; images were 
acquired every 5 min with 4 µm z-section thickness for 24 hrs. Images acquired with SoftWoRx 
v1.2.   
Antibodies/stains used include: anti-CEP135 (cells-1:500; tissue-1:100; Abcam 
ab75005), anti-γ-tubulin (cells-1:500; tissue-1:100; Sigma Aldrich GTU-88), anti-E-
Cadherin/M168 (1:100; Abcam ab76055), anti-Centrin-3/3E6 (1:500; Abnova H00001070-
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M01), anti-phospho-Histone H3 (1:1000; Cell Signaling Technology #9706S), 7-AAD Staining 
Solution (1:50; BioLegend #420404), Alexa Fluor™ 647 Phalloidin  (1:40; ThermoFisher 
A22287), anti-α-tubulin (1:1500; Sigma Aldrich DM1A), anti-CENP-C (1:1000; MBL 
International PD030), anti-LaminA/C (1:100; Santa Cruz Biotechnology sc-6215), anti-Emerin 
(1:100; Sigma-Aldrich HPA000609), anti-β1 integrin (1:1000, DSHB AIIB2), anti-α6 
integrin/CD49f (1:100; produced in our lab), anti-CD44 (1:100; ThermoFisher #156-3C11), anti-
N-Cadherin (1:100; Santa Cruz Biotechnology sc-8424), anti-CK5/14 (1:100; produced in our 
lab), anti-CK18 (1:100; Abcam EPR1626), anti-Vimentin (1:100; Cell Signaling Technology 
D21H3), anti-Desmin (1:100; Atlas Antibodies HPA018803), Hyaluronic Acid-Binding Protein 
(1:100; Sigma-Aldrich #385911), anti-cMyc (1:50-100; Cell Signaling Technology D3N8F), 
anti-FOXA1(1:100; Abcam EPR10881), anti-Synaptophysin (1:100; Sigma-Aldrich MRQ-40), 
anti-laminin-332 (1:200; Abcam ab14509), anti-ITGB4 (1:100; Abcam ab110167), and anti-p63 
(1:100; biobyt orb214808). Secondary antibodies (Jackson Immunoresearch) were used at 
1:1500. 
 
Animal studies   
Mouse experiments were conducted with animal care and committee approval using the 
Experimental Mouse Shared Service.  10x106 prostate epithelial cells were mixed with an equal 
number of non-tumorigenic fibroblasts (WPMY-1) in 0.1 ml growth factor reduced matrigel and 
injected subcutaneously into male NOD/SCID/IL2Rγnull (NSG) mice (Jackson Laboratories); 
three mice per treatment group.  Tumor growth was measured 2 times/week and tumor volume 
estimated according to the formula: [(width)2 x length]/2.  Animals were terminated by CO2 
when total tumor reached 2000 mm3.  
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Statistical Analysis   
The statistical significance of differences in average measurements was evaluated using unpaired 
t-tests (GraphPad Prism 6.0).  Means are significantly different if P<0.05.  In figures, “*” 
indicates 0.05>P≥0.01; “**”0.01>P≥0.001; “***”0.001>P≥0.0001; “****”0.0001>P, and not 
significant “ns” indicates P≥0.05 for indicated pairwise comparisons.   Error bars in all figures 
indicate standard deviation (SD). 
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Figure Legends 
Fig. 1  Primary prostate tumors display centrosome loss. 
a  Normal human prostate tissue contains E-Cadherin (green) on cell borders and CEP135 (red) 
on centrosomes.  DNA (blue).  Centrosomes in individual cells were identified within a complete 
z-series of the tissue.  (Left) A single z-section shows normal gland structure.  Scale, 100 µm.  
(Middle) Maximum intensity projection of region (white box in left panel) showing centrosome 
distribution.  Scale, 10 µm. (Right) Selected single z-sections (from box in middle panel) 
displaying distinct centrosomes.  Labels identify specific z-sections.  Scale, 5 µm; 1 µm (insets).   
b  Centrosomes in a low grade (Gleason 3) PCa gland detected as in (a).  Scale, 10 µm.  Insets 
are from boxed regions in larger image and are maximum intensity projections showing cells 
with two (left) and zero centrosomes (right) at higher magnification.  Scale, 5 µm. 
c Region of high grade (Gleason 5) PCa.  Centrosomes are absent in cancer cells (identified by 
positive E-Cadherin immunostaining; delineated  by white-dashed lines) but are visible in the 
surrounding stroma (yellow arrowheads).  Scale, 10 µm.   
d, e  Tissue of normal human mammary gland (d) and triple negative breast cancer (TNBC) (e).  
Scale, 100 µm (left panels); 10 µm (right panels); 5 µm (large insets); 1 µm (small insets).   
f  Number of centrosomes (CEP135 foci or γ-Tubulin foci) per cell in normal prostate, PCa, 
normal breast, and TNBC tissue cells.  n>100 cells from 3 independent experiments in a total of 
16 different patient samples.  Data are means ± SD.  Cells with >2 centrosomes show 
amplification.  Differences were tested for significance using unpaired t-tests; *p < 0.05; **p < 
0.01. 
 
Fig. 2  Centrosome numbers are altered in PCa lines.  
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Immunostaining of centriole proteins CEP135 (red), CENT3 (green), or γ-tubulin (green) in 
primary (PEC) (a) and immortalized non-tumorigenic prostate epithelial cells (b-d), and PCa cell 
lines (e-i).  DNA, blue.  Boxed regions are shown at higher magnification in insets.  
j  PCa cell lines contain an altered centrosome number.  Data are means ± SD (n= 100 cells, 2 
independent experiments for PEC, and 3 independent experiments for all other cell lines).  PCa 
lines displaying centriole loss (significantly larger % of cells with 0 centrosomes) and 
amplification (significantly larger % with >2 centrosomes) are indicated by black and red lines, 
respectively.  Significant differences were evaluated with a two-tailed, unpaired t-test; *p < 0.05; 
**p < 0.01; ***, p < 0.001. 
 
Fig. 3  Centrosome loss increases the frequency of mitotic errors, chromosome fragmentation 
and micronuclei.  
a,b Percentages of RWPE1 or PrEC cells with the indicated centrosome number after treatment 
with centrinone (300 nM) for the indicated number of days, followed by washout (WO).  (b)  
Centrinone treatment does not change centrosome number in RWPE1 cells expressing 
centrinone-resistant mutant Plk4(G95L). Data are means ± SD (n= 300 cells, 3 independent 
experiments for each treatment or time point).  Centrosome numbers in Plk4(G95L) expressing 
cells at Day 0 and Day10 of centrinone treatment are not significantly different. 
c Selected frames from time-lapse videos of representative mock and centrinone-treated mitotic 
RWPE1 and PrEC cells stably expressing histone H2B-GFP and CETN1-tdTomato (not shown) 
to label chromosomes and centrioles, respectively.  Anaphase lagging chromosomes (red 
arrowheads) and small chromosome fragments (yellow arrowheads) are indicated.  Numbers 
indicate time (mins) prior to anaphase onset.  See Supplementary Videos 1-4.   
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d Measurements of mitotic duration (nuclear envelope breakdown to telophase) in mock, DMSO, 
and centrinone-treated RWPE1 (top) and PrEC (bottom) cells.  Centrinone treatment 
significantly slows mitotic progression. Number of cells analyzed: RWPE1: WT=87, DMSO=77, 
centrinone=88; PrEC: WT=90, DMSO=100, centrinone=100. Data are means ± SD. Significant 
differences tested using two-tailed, unpaired t-tests; ****, p < 0.0001.   
e  Mitotic RWPE1 cell treated with centrinone and stained with Alexa Fluor™ 647 Phalloidin 
(red) and expressing histone H2B-GFP (green).  Arrowheads indicate chromosome fragments. 
Scale, 10 µm.   
f  Mitotic RWPE1 cell treated with centrinone and immunostained for centromeric protein 
CENP-C (red) and microtubules (green).  DNA, blue.  Arrowheads mark chromosome fragments 
lacking centromeric protein CENP-C.  Scale, 10 µm.  See Supplementary Videos 7 and 8. 
g  Percentage of RWPE1, PWPE1-Plk4(G95L), PrEC, and PrEC-Plk4KO cells containing 
micronuclei.  Data are means ± SD (n>300 cells from 3 independent experiments).  Statistical 
significance evaluated using a two-tailed, unpaired t-test; **, p < 0.01; ‘ns’, not significant. 
h Centrinone-treated RWPE1 cells were immunostained for the centromeric protein CENP-C to 
establish the presence of centromeres within micronuclei.  Data are means ± SD (n>30 
micronuclei from 3 independent experiments). 
i  Spheroids of RWPE1 cells were treated with DMSO or centrinone from days 6 to 13, and 
stained on day 13 to label DNA. Arrowheads mark micronuclei.  Scale, 10 µm.   
 
Fig. 4  Centrosome loss produces abnormal nuclear envelopes and multinucleate cells whose 
number significantly increases with Gleason grade. 
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a  Selected frames from time-lapse movies of mock and centrinone-treated mitotic RWPE1-
H2B-GFP and PrEC-H2B-GFP cells.  Arrowheads mark nuclear envelope defects including 
invaginated (red), multinucleated (green), and multilobed (orange) morphologies.  Scale, 10 µm.   
b  RWPE1 and PrEC cells were treated with DMSO or centrinone for 15 days and then stained 
with Alexa Fluor 647 Phalloidin (red) and nuclear envelope markers Lamin A/C or Emerin 
(green).  DNA, blue.  Arrowheads mark nuclear envelope invaginations.  Scale, 10 µm.  
c,d Percentages of multinucleated cells after treatment with DMSO or centrinone for 15 days in 
RWPE1 and PrEC cells (c) or in the indicated cell line (d).  Data are means ± SD (n>300 cells 
from 3 independent experiments).  Statistically analyzed using a two-tailed, unpaired t-test; ***, 
p < 0.001; ****, p < 0.0001.   
e  Human prostate cancer tissue contains multinucleated cells. Tissue was stained for E-Cadherin 
(green) and nuclear envelope markers Lamin-A/C or Emerin (red).  DNA, blue.  Dashed lines 
trace the E-Cadherin-positive cell borders of individual PCa cells.  All images are single sections 
selected from a z-stack.  Boxed regions are shown at higher magnification and highlight 
individual multinucleated cells.  Arrowhead marks a micronucleus.  Scale, 100 µm in the upper 
left panel; 10 µm in all other panels.   
f  Percentages of multinucleated cells of human PCa tissue.  Data are means ± SD.  n>50 total 
cells from at least 3 different patients in a total 26 patient samples.  Statistical differences tested 
using a two-tailed, unpaired t-test; *, p < 0.05; **, p < 0.01. 
g  Human prostate cancer tissue contains multinucleated cells that lack centrosomes. Tissue was 
immunostained for E-Cadherin (green) and CEP135 (red).  DNA, blue.  This maximum intensity 
projection shows a binucleate cell (yellow arrowhead), and dashed lines trace the two nuclei.  
Note the absence of CEP135 foci.  Scale, 10 µm.   
 37 
h  Most multinucleated cells in human PCa tissue have a decreased number ofcentrosomes (<2 
CEP135 foci per cell).  Data are means ± SD.  n=18 patients with multinucleated cells.  
Statistical differences were tested using a two-tailed, unpaired t-test; *, p < 0.05; **, p < 0.01. 
 
Fig. 5  Centrosome loss results in aneuploidy and chromosomal rearrangements. 
a  Metaphase spreads of RWPE1 cells treated with DMSO or centrinone for 15 days.  
Arrowheads indicate chromosome fragments.  Scale, 10 µm.   
b  Chromosome numbers per cell in mock, DMSO, or centrinone-treated RWPE1 cells.  Data are 
means ± SD (n=40 mock, 30 DMSO, and 79 centrinone-treated cells).  Statistical differences 
were tested using a two-tailed, unpaired t-test with Welch’s correction; ***, p < 0.001; ****, p < 
0.0001.   
c  Cell cycle profiles of 15-day DMSO or centrinone treated RWPE1 and RWPE1-Plk4(G95L) 
cells analyzed by flow cytometry.  Profiles are gated to show the percentages of cells with 2N 
(diploid) and >4N (aneuploidy) DNA content.  Note that the frequency of aneuploidy increases 
>6-fold after centrinone treatment but not in centrinone-resistant Plk4 (G95L) mutant RWPE1 
cells.   
d, e  Representative spectral karyotyping (SKY) images of passage 9 RWPE1 cells grown in 
keratinocyte serum-free medium (d) and passage 18 RWPE1 cells grown with 10% FBS (e). 
Cells were mock or centrinone treated for 15 days.   
f, g  Heat-maps of chromosome copy numbers determined by SKY from RWPE1 cells in (d) and 
(e).  Twenty cells were analyzed for each condition.  Heat scales indicate chromosome copy 
number.  “X”, no detection. 
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Fig. 6  Chronic or transient centrosome loss in non-tumorigenic cells increases their potential to 
form malignant xenograft tumors.   
a Number of xenograft tumors formed from parental PrEC (4 injections), PrEC-Plk4KO-1 (8 
injections), and PrEC-Plk4KO-2 (8 injections) cell lines.  
b, c Sections of PrEC-Plk4KO tumor stained with hematoxylin and eosin. (b) Low magnification 
of tumor section shows streams of tumor cells invading surrounding smooth muscle and fat 
layers. (c) Tumor section at low (left) and high (right) magnification shows proliferative cells 
and nuclear atypia.  Mitotic cells (red arrowhead), enlarged nuclei (green arrowhead), and 
multinucleated cells (yellow arrowheads) are indicated. Scale, 100 µm. 
d  Scheme used to select PrEC clones following transient centrosome depletion.  PrEC cells were 
treated with centrinone (300 nM) for 15 days and cultured in normal growth medium after 
monoclonal expansion.  Clones containing MYC and ERG protein levels consistent with PCa 
progression were selected (CTN1, 6, and 9) and subcutaneously injected into NOD/SCID male 
mice.   
e  Tumor volume growth curves from CTN-1, 6, and 9 injections (12 injections for each CTN 
clone are plotted).  Number of tumors formed is indicated above. 
f  Kaplan-Meier tumor-free survival as evaluated by the presence of xenograft tumors.  Data 
represent n=12 injection sites per clone (CTN-1, 6, and 9), total of 9 mice. 
g  Centrinone-derived PrEC tumor stained with hematoxylin and eosin (H&E).    Boxed region is 
shown at higher magnification (right).  Scale, 100 µm. 
h  An H&E-stained tissue section of a centrinone-derived PrEC tumor showing invasion through 
the adjacent muscle layer. Arrowheads indicate strands of tumor cells invading muscle.  Scale, 
100 µm. 
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i  CTN-9 tumor section immunostained for centrosome marker CEP135 (red).  DNA, blue.  
Individual cells are shown at higher magnification in the boxed regions.  Scale, 10 µm; 1 µm 
right panels. 
j  Mitotic cells in CTN-9 tumors containing centrosome-associated (left) and acentrosomal 
(right) spindles.  CEP135 (red), microtubules (green) and DNA (blue).  Scale, 10 µm.  
k  Centrosome numbers in CTN tumors.  n=100 number of cells counted per tumor.   
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Supplementary Figure Legends 
Fig. S1  Centrosome markers co-localize in human prostate cancer FFPE tissue samples. 
Human prostate cancer FFPE tissue sample immunostained for a pericentriolar material marker 
γ-tubulin (green), an epithelial cell border marker CD49f/integrin α6 (red, left panel), or the 
centriole marker CEP135 (red, middle panel).  Hoechst-stained DNA, blue.  Left panel scale, 100 
µm.  Boxed region in left panel is shown at higher magnification in middle panel.  Middle panel 
scale, 10 µm.  Arrowhead marks two CEP135 foci in an individual cell shown at higher 
magnification in the right panels.  Right panel scale, 0.125 µm. 
 
Fig. S2  Centrosome loss decreases the growth rate in immortalized prostate epithelial RWPE1 
cells and prolongs mitosis in both RWPE1 and PrEC cells.  
a  Cross-correlative scatter plots show cell cycle profiles of RWPE1 cells treated with DMSO or 
centrinone.  Cells were stained with 7-AAD to label DNA and immunostained with anti-
phospho-histone H3 antibody (pH3) to label mitotic cells, and then analyzed by flow cytometry.   
b  Quantification of the mitotic indices of RWPE1 cells and RWPE1-Plk4(G95L) cells treated 
with DMSO or centrinone.  Cells were labeled with the DNA stain, 7-AAD, immunostained with 
mitosis-specific anti-phospho-histone H3 antibody (pH3), and analyzed by flow cytometry.  Data 
are means ± SD (3 independent experiments).  Differences were tested for statistical significance 
using a two-tailed, unpaired t-test; ****, p < 0.0001; ‘ns’, not significant.   
c  Images showing nuclei and micronuclei (yellow arrowheads) in Hoechst-stained RWPE1 cells 
treated with DMSO or centrinone. Scale, 10 µm. 
d  Agarose gel of products of PCR reactions to detect Plk4 DNA.  The presence of Plk4-
encoding genomic DNA in control (wild-type Plk4; WT) PrEC cell lines and CRISPR-generated 
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Plk4-knock-out (Plk4KO) PrEC clones was tested by PCR, using purified genomic DNA as 
templates and PCR primers flanking the CRISPR guide-cutting region. 
e  q-RT-PCR analysis of the PrEC control and PrEC-Plk4KO clonal cells.  Plk4 mRNA is absent 
in the Plk4KO clones.  Data (ratios of measured Plk4:GAPDH) are normalized to the ratio of the 
parental (WT) PrEC cells. 
 
Fig. S3  Chromosomal rearrangements in centrinone-treated RWPE1 and PrEC cells. 
a, b  SKY analysis of centrinone-treated RWPE1 cells (a) and PrEC CTN-9 cells (b) revealed 
chromosome translocations unique to treated cells that were not seen in untreated cells (though 
some translocations were seen in untreated cells [Fig. S5a]).  Numbers indicate the source 
chromosomes for the fragments present in the translocation products. 
 
Fig. S4  Screening centrinone-treated PrEC clones for PCa features. 
a, b  C-MYC (a) or ERG (b) protein levels in clonal cell populations were measured by flow 
cytometry.  Protein levels were measured in untreated PrEC cells as well as 10 different PrEC 
clonal lines derived after DMSO or centrinone treatment.  The fold change of C-MYC or EGR 
protein level relative to the level in untreated PrEC cells is plotted for each cell line.  Clones 1, 6, 
and 9 were selected for injection and evaluated for tumor formation in mice. 
c  Graph shows mean percentages of cells with the indicated number of centrosomes.  Data are 
shown as means ± SD (n= 300 cells from 3 independent experiments).  No significant differences 
were noted between these cell lines.  Centrosomes were counted after cells recovered from 
treatments (explaining the restoration of normal centrosome numbers in centrinone-treated cells) 
and just prior to injection of the cells into mice. 
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d  The percentages of cells containing micronuclei.  Data are means ± SD (n=300 from 3 
independent experiments).  Differences were tested for statistical significance using a two-tailed, 
unpaired t-test; *, p < 0.05; ***, p < 0.001; ****, p < 0.0001.   
d  Images of mitotic chromosome spreads prepared from the untreated PrEC (initial) cell line and 
the centrinone-treated clonal lines, before injection.  The number of chromosomes in each spread 
is noted (top right corner). 
 
Fig. S5  Characterization of PrEC-CTN xenograft tumors and cells isolated from CTN tumors. 
a, b  Representative SKY images of an untreated PrEC cell (a) and a PrEC clone 9 (CTN-9) cell 
(b).  Arrowheads indicate examples of chromosomal rearrangements. 
c  Expression levels of different epithelial and mesenchymal markers expressed in CTN-9 
tumors.  Protein levels were determined from the immunostaining intensities of the FFPE tissue 
section.  Mucin production was detected by muscicarmine staining.   -/-, not detectable; +/- 
heterogeneously expressed; ++, strongly expressed. 
d  Immunofluorescence images of cells from a CTN-9 xenograft tumor (top row) and from 
human PCa tissue (bottom row) immunostained with the indicated epithelial, mesenchymal, and 
secretory markers. The human PCa tissue served as a positive control for immunostaining.  
Scale, 10 µm. 
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Supplementary Video Legends 
Supplementary Video 1.  Mitosis in a mock-treated RWPE1 cell. 
Time-lapse movie shows a representative mitotic RWPE1 cell stably co-expressing histone 
H2B-GFP (green) and CNTN1-tdTomato (red) to label chromosomes and centrioles, 
respectively. This cell established a bipolar spindle and segregated its duplicated genome into 
two daughter cells. Frames were generated from maximum intensity projections of z-stacks 
captured every 5 minutes.  Scale, 10 µm. 
 
Supplementary Video 2.  Mitosis in a centrinone-treated RWPE1 cell. 
Time-lapse movie of a representative centrinone-treated mitotic PrEC cell stably co-
expressing histone H2B-GFP and CETN1-tdTomato. This centrosome-less cell displayed a 
prolonged delay in prometaphase with a central clustered chromosome mass.  Eventually, the 
cell displays cytokinesis failure, generating a single multinucleated daughter cell.  Each frame 
is a maximum intensity projection of a z-stack captured every 5 minutes.  Scale, 10 µm. 
 
Supplementary Video 3.  Mitosis in a mock-treated RWPE1 cell. 
Time-lapse movie shows a representative mitotic RWPE1 cell stably expressing histone H2B-
GFP. This cell established a bipolar spindle and segregated its duplicated genome into two 
daughter cells. Frames were generated from maximum intensity projections of z-stacks 
captured every 5 minutes.  Scale, 10 µm. 
 
Supplementary Video 4.  Mitosis in a mock-treated PrEC cell. 
Time-lapse movie of a representative mitotic PrEC cell stably expressing histone H2B-GFP. 
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This cell established a bipolar spindle and segregated its duplicated genome into two daughter 
cells. Each frame is a maximum intensity projection of a z-stack captured every 5 minutes.  
Scale, 10 µm. 
 
Supplementary Video 5.  Mitosis in a centrinone-treated RWPE1 cell. 
Time-lapse movie of a representative centrinone-treated mitotic RWPE1 cell stably 
expressing histone H2B-GFP.  This cell established a bipolar spindle and segregated its 
duplicated genome. Note the prolonged delay in prometaphase and monopolar spindle. 
Subsequently, the cell displays cytokinesis failure, generating a single multinucleated 
daughter cell.  Chromosome fragments are present throughout mitosis. Each frame is a 
maximum intensity projection of a z-stack captured every 6 minutes.  Scale, 10 µm. 
 
Supplementary Video 6.  Mitosis in a centrinone-treated PrEC cell. 
Time-lapse movie of a representative centrinone-treated mitotic PrEC cell stably expressing 
histone H2B-GFP. At the beginning of the movie, this cell contains a monopolar spindle with 
peripheral small H2B-containing elements, which are presumably unattached chromosome 
fragments. Eventually the spindle becomes pseudo-bipolar. Lagging chromosomes and 
chromosome fragments are visible during anaphase.  Each frame is a maximum intensity 
projection of a z-stack captured every 5 minutes.  Scale, 10 µm. 
 
Supplementary Video 7.  Chromosome fragments in a centrinone-treated RWPE1 mitotic cell. 
Movie generated by stepping through each section of a z-stack taken of a centrinone-treated 
mitotic RWPE1 cell. The cell was immunostained for α-tubulin (green) to mark microtubules 
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and CENP-C (red) to mark centromeres. DNA (blue). Note the presence of small chromosome 
fragments lacking CENP-C and not attached to microtubules. The step size for each z-section 
was 0.2 um, for a total stack depth of 7.8 um. Scale, 10 µm. 
 
Supplementary Video 8.  Bipolar spindle in a centrinone-treated RWPE1 mitotic cell. 
Movie generated by stepping through each section of a z-stack taken of a centrinone-treated 
mitotic RWPE1 cell immunostained for α-tubulin (green) to mark microtubules, and CENP-C 
(red) to mark centromeres. DNA (blue). Note the acentrosomal, bipolar spindle. The step size 
for each z-section was 0.2 um, for a total stack depth of 7.8 um. Scale, 10 µm. 
 
Supplementary Video 9.  Abnormal nuclear envelope reformation in a dividing centrinone-
treated RWPE1 cell. 
Time-lapse movie of a centrinone-treated mitotic RWPE1 cell stably expressing histone H2B-
GFP.  The cell eventually establishes a bipolar spindle and proceeds through anaphase A with 
no obvious defects.  However, chromosomes reform into abnormally-shaped nuclei during 
telophase. Each frame is a maximum intensity projection of a z-stack captured every 5 
minutes.  Scale, 10 µm. 
 
Supplementary Video 10.  Abnormal nuclear envelope reformation in a dividing centrinone-
treated PrEC cell. 
Time-lapse movie of a centrinone-treated mitotic PrEC cell stably expressing histone H2B-
GFP.  A bipolar spindle eventually formed, and anaphase A proceeded with no obvious 
defects.  However, abnormally-shaped nuclear envelopes reformed during telophase. Each 
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frame is a maximum intensity projection of a z-stack captured every 5 minutes.  Scale, 10 µm. 
 
 











